Skip to main content

Table 2 Estimated standardized mean difference between treatment groups before and after propensity score weighting

From: Effects of second-line antihyperglycemic drugs on the risk of chronic kidney disease: applying a target trial approach to a hospital-based cohort of Thai patients with type 2 diabetes

Variables

Standardized differences

Variance ratio

Raw

Weighted

Raw

Weighted

TZD vs. SU

    

Age, year

− 0.1263

− 0.0201

0.9809

1.0076

Male vs. Female

0.0043

− 0.0027

1.0016

0.9991

BMI, kg/m2

0.2837

− 0.0231

1.3183

0.9799

ln(FPG), mg/dL

− 0.2419

0.0511

0.8574

1.2458

HT

0.0012

− 0.0129

0.9984

1.0205

eGFR group < 90 ml/min/1.73 m2

− 0.1037

− 0.0084

1.0659

1.0057

CVD

− 0.1110

− 0.0004

0.6654

0.9989

Statin

0.1172

− 0.0205

0.8915

1.0186

HDL-C, mg/dL

0.0847

− 0.0100

1.0447

1.0442

Triglycerides, mg/dL

− 0.0717

0.0803

1.0053

8.9630

LDL-C, mg/dL

− 0.0729

− 0.0042

0.9187

1.0439

ACEi/ARB

0.0373

− 0.0142

1.0013

0.9991

DPP4i vs. SU

    

Age, year

0.2436

− 0.0111

1.0056

1.0908

Male vs. Female

− 0.0374

0.0074

0.9870

1.0023

BMI, kg/m2

0.0280

0.0019

1.0991

1.0250

ln(FPG), mg/dL

− 0.1617

0.0065

0.9541

1.1660

HT

0.1247

0.0027

0.8056

0.9957

eGFR group < 90 ml/min/1.73 m2

− 0.0207

0.0003

1.0149

0.9998

CVD

0.2104

− 0.0020

1.7271

0.9940

Statin

0.1275

− 0.0080

0.8810

1.0073

HDL-C, mg/dL

− 0.0031

− 0.0053

1.1262

1.1293

Triglycerides, mg/dL

− 0.0624

0.0109

0.7698

1.1319

LDL-C, mg/dL

− 0.1704

0.0227

1.0567

1.2859

ACEi/ARB

0.0200

0.0015

1.0011

1.0001

SGLT2i vs. SU

    

Age, year

− 0.1716

0.0036

1.1340

0.9964

Male vs. Female

0.0872

0.0154

1.0233

1.0048

BMI, kg/m2

0.5720

0.0204

1.6763

1.1053

ln(FPG), mg/dL

− 0.4200

0.1604

0.6622

1.1047

HT

0.1278

0.0657

0.8029

0.8939

eGFR group < 90 ml/min/1.73 m2

− 0.3782

− 0.0722

1.1352

1.0444

CVD

0.5425

0.0225

2.8544

1.0672

Statin

0.1855

0.1306

0.8224

0.8670

HDL-C, mg/dL

 − 0.1733

0.0041

0.9205

1.1982

Triglycerides, mg/dL

− 0.0259

− 0.1194

1.0624

0.5776

LDL-C, mg/dL

− 0.2757

− 0.0246

1.1049

1.3047

ACEi/ARB

0.0897

0.0026

1.0009

1.0001

  1. ACEi: Angiotensin-converting enzyme inhibitors; ARB: Angiotensin receptor blockers; BMI: Body mass index; CVD: Cardiovascular disease; DPP4i: Dipeptidyl peptidase-4 inhibitors; eGFR: Estimated glomerular filtration rate; FPG: Fasting plasma glucose; HDL-C: High density lipoprotein cholesterol; HT: Hypertension; LDL-C: Low density lipoprotein cholesterol; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; SU: Sulfonylureas; TZD: Thiazolidinediones
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840